Therefore, assessment of the levels of JAK2 gene expression, phosphorylated, and total JAK2 proteins at the time of diagnosis could be considered in predicting therapeutic responses among patients with chronic phase CML treated with imatinib. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.